Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-595-4 | CAS number: 97-62-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
For this enpoint, read-across information on the source substance 3-methylbutyl isovalerate is available.
As the combined results of 3 in vitro / in chemico tests resulted in an inconclusive outcome, the substance was tested in vivo in a GPMT test. In this test, 3-methylbutyl isovalerate was found to not be a skin sensitizer.
As a consequence, the target substance ethyl isobutyrate was also considered to be not a skin sensitizer.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation, other
- Remarks:
- an in vivo skin sensitization (non-LLNA) study was performed based on ambigious results in the in vitro test battery
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- Read-across from 3-methylbutyl isovalerate to ethyl isobutyrate is considered justified based on strong similarities with regard to chemical structure and metabolic pathways. A full read-across justification including comparison of toxicological profiles will be included in section 13 of the IUCLID dossier.
- Reason / purpose for cross-reference:
- read-across source
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 100%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Remarks on result:
- no indication of skin sensitisation
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 100%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Remarks on result:
- no indication of skin sensitisation
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Read-across was done from 3-methylbutyl isovalerate. Based on this result, and on the structural, chemical and toxicological similarities between 3-methylbutyl isovalerate and ethyl isobutyrate, ethyl isobutyrate did not provoke an allergic response, and is therefore not sensitising.
- Executive summary:
Read-across was done from 3-methylbutyl isovalerate. In a study on 3-methylbutyl isovaleratew the skin sensitizing potential was assesssed by means of a maximization test using guinea pigs according to OECD 406 and GLP.
In a preliminary test topical application did not reveal any evidence of adverse skin reactions, therefore, the induction sites in the main test for each group were pretreated with 10% sodium dodecyl sulfate prior to the second induction.
There were 2 groups, one for 3-methylbutyl isovalerate, this group consisted of 10 animals, while the second group was the control group made of 5 animals. In the test group, a concentration of 25% of 3-methylbutyl isovalerate was injected intradermally for the first induction. The second induction was conducted with 100% of 3-methylbutyl isovalerate. The sites were occluded for 48 hours, whereafter the challenge was conducted with 100% of the test substance. Hereafter, the sites are occluded for 24 hours. In the control group, the first and second inductions were done with olive oil and the challenges with the 100% of the test substance and olive oil.
Both in the control and the test group no skin reactions such as redness or swelling were observed in any animal at 24 and 48 hours after the challenge patch was removed. During the observation period, no abnormalities in clinical signs or body weight gain were observed in any animal of any group. Based on the result of this study, 3-methylbutyl isovalerate did not produce skin sensitization under the conditions of this study. Therefore, 3-methylbutyl isovalerate does not have to be classified as sensitising.
Based on this result, and on the structural, chemical and toxicological similarities between 3-methylbutyl isovalerate and ethyl isobutyrate, ethyl isobutyrate is considered to be not sensitising.
Reference
CLINICAL OBSERVATIONS: No abnormal signs or symptoms were observed in any animal of any group throughout the course of the study.
BODY WEIGHTS: All animals exhibited normal body weight gain.
POSITIVE CONTROL: The sensitization rate of CDNB was 100% and the sensitization grade was classified to be ‘V (Extreme)’. Consequently, the study was considered to be valid.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
For this endpoint there are 4 studies available on the read-across substance 3-methylbutyl isovalerate.
In a first step to evaluate the skin sensitisation effects of 3-methylbutyl isovalerate a combination of 3 in vitro methods addressing the key events of the adverse outcome pathway (AOP) for skin sensitization were performed. The tests are the Direct Peptide Reactivity Assay (DPRA), the ARE Reporter Assay (LuSens) and the Dendritic Cell Line Activation Assay (h-CLAT).
DPRA test
In the DPRA test (OECD 442C) the reactivity of 3-methylbutyl isovalerate towards synthetic cysteine (C)- or lysine (K)- containing peptides was evaluated. Incubation of the synthetic peptides with 3-methylbutyl isovalerate was done for 24 hours and the remaining concentrations of cysteine- or lysine-containing peptides were determined.
The mean C-peptide depletion was -1.09% and the mean K-peptide depletion was -1.20%.
Based on the results it was concluded that 3-methylbutyl isovalerate shows a minimal chemical reactivity in the DPRA under the test conditions. However, due to the limited solubility of 3-methylbutyl isovalerate the samples with both peptides were emulsions and the result could therefore be underpredictive. Following the OECD TG 442C the study should be considered as “inconclusive".
LuSens test
In the LuSens assay (OECD 442D) the keratinocyte activating potential of 3-methylbutyl isovalerate was evaluated. 3-methylbutyl isovalerate was incubated with a luciferase reporter cell line (LuSens cells) for 48 hours and the antioxidant response element (ARE) dependent luciferase activity was measured, in parallel to a MTT assay to assess the cytotoxicity. No precipitates were noticed in any preparations. The acceptance criteria were met. Exposure to 3-methylbutyl isovalerate did not induce a statistical significant increase in the luciferase activity in LuSens cells while 70% viability was reached. In other words, 3-methylbutyl isovalerate is to be considered as a non-sensitiser.
h-CLAT test
In the third in vitro study (OECD 442E) the potential of 3-methylbutyl isovalerate to induce the expression of the cell membrane markers CD86 and CD54 in the human Cell Line Test (h-CLAT) was evaluated. In the human pro-monocytic cell line THP-1 the change in the expression of the cell membrane markers is measured by flow cytometry after 24 hours of test substance exposure through staining with FITC labeled anti-human-CD86/anti human CD54 antibody and propidium iodide.
No precipitates were noticed at any concentration. The EC200 (the concentration resulting in a RFI of 200) for CD54 was calculated to be 482 µg/mL in experiment 2 and 757 µg/mL in experiment 3. 3-methylbutyl isovalerate induced CD54 expression in THP-1 cells with at least 50% viability in at least two independent experiments, thus it induces dendritic cell activation.
Conclusion in vitro tests
The test battery evaluation uses the results of the three individual assays reflecting three key events along the adverse outcome pathway leading to skin sensitization. In the test battery a weight of evidence approach is made in such a way that any 2 out of 3 tests determine the overall result (2 positive test results drive the prediction of a sensitizer, while 2 negative test results drive the prediction of a test substance to be a non-sensitizer).
In the case of 3-methylbutyl isovalerate 1 of the test is inconclusive, 1 is negative and 1 is positive. The test battery indicates contradictory results and thus an evaluation is not possible. For this reason a follow-up in vivo test was necessary.
In vivo study
In the in vivo study the skin sensitizing potential of the test item was assessed in a maximization test using guinea pigs according to OECD 406 and GLP.
In a preliminary test topical application did not reveal any evidence of adverse skin reactions, therefore, the induction sites in the main test for each group was pretreated with 10% sodium dodecyl sulfate prior to the second induction. There were 2 groups, one for the test substance and one for the negative control. In the test group, a concentration of 25% of the test substance was injected intradermally for the first induction. The second induction was conducted with 100% of the test substance. The sites were occluded for 48 hours, whereafter the challenge was conducted with 100% of the test substance. Hereafter, the sites are occluded for 24 hours. In the control group, the first and second inductions was done with olive oil and the challenges with the 100% of the test substance and olive oil.
Both in the control and the test group no skin reactions such as redness or swelling were observed in any animal at 24 and 48 hours after the challenge patch was removed. During the observation period, no abnormalities in clinical signs or body weight gain were observed in any animal of any group. Based on the result of this study, the test substance did not produce skin sensitization under the conditions of this study. Thus, the test article does not have to be classified as sensitising in the in vivo study.
Based on this result, and on the structural, chemical and toxicological similarities between 3-methylbutyl isovalerate and ethyl isobutyrate, ethyl isobutyrate is not considered to provoke skin sensitization in a maximization test with guinea pigs.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
The criteria to classify a substance for the skin sensitisation endpoint using the results of a maximization study according to the CLP Regulation (EC) No 1272/2008 are set out in Tables 3.4.3 and 3.4.4 for the sub-categories. Since no animals showed an allergic response in the GPMT test with 3-methylbutyl isovalerate, this substance does not have to be classified as sensitising.
Based on this result, and on the structural, chemical and toxicological similarities between the 3-methylbutyl isovalerate and ethyl isobutyrate, ethyl isobutyrate is not classified as sensitising.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.